Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biovest International has received notice from the US Internal Revenue Service (IRS) that it was approved to receive a $245,000 Federal grant under the Qualifying Therapeutic Discovery Project.
Subscribe to our email newsletter
Headquartered in Tampa, Florida, Biovest International, in collaboration with the National Cancer Institute, has developed a patient-specific, cancer vaccine, BiovaxID, with three clinical trials completed, including a Phase III study, demonstrating evidence of safety and efficacy for the treatment of indolent follicular non-Hodgkin’s lymphoma and mantle cell lymphoma.
The current grant will support the advancement of company’s BiovaxID for the treatment of non-Hodgkin’s lymphoma.
Biovest president general counsel Samuel Duffey said that it is very gratifying for the promise of BiovaxID to be recognised with this cash award from the Therapeutic Discovery Project, and they are continuing to pursue other sources of non-dilutive funding including from Federal and State sources.